Gefitinib

吉非替尼

Report date: 2026/05/20 20:02:01
NMEFirst In Class

Base Information

Drug NameGefitinib
Drug Alias Name吉菲特尼Gefitinibum易瑞沙IressaZD-1839
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionEGFR 19del inhibitorsEGFR L858R inhibitorsEpidermal growth factor receptor erbB1 inhibitors
TargetsEpidermal growth factor receptor erbB1EGFR 19delEGFR L858R
Therapy Area/IndicationsMedullary thyroid cancer (MTC)Brain metastasesCNS Embryonal Tumor +[77] 
Global Approved IndicationsCarcinoma, Non-Small-Cell Lung
Approved Indications in ChinaCarcinoma, Non-Small-Cell Lung
Original Approved Country/TerritoryJapan
Original Approved Date2002/07/05
Country/TerritoryCzechiaBelgiumBulgaria +[46] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesAstrazeneca Plc
China Registration ClassN/A

Develop Information

Active CompaniesAstrazeneca Pharmaceutical Co LtdAstrazeneca Uk LtdAstrazeneca Ab
Inactive CompaniesDana-Farber Cancer InstituteUT Health San AntonioUniversity of Zurich +[29] 
Active IndicationsCarcinoma, Non-Small-Cell Lung
Inactive IndicationsMedullary thyroid cancer (MTC)Brain metastasesCNS Embryonal Tumor +[76] 

Other Information

ATC CodeL01EB01
Related LinksWikipediaDrugBankKEGG